Legacy Private Trust Co. Has $7.42 Million Stock Position in Eli Lilly and Company (NYSE:LLY)

Legacy Private Trust Co. increased its holdings in Eli Lilly and Company (NYSE:LLY) by 10.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,616 shares of the company’s stock after acquiring an additional 904 shares during the period. Legacy Private Trust Co.’s holdings in Eli Lilly and Company were worth $7,424,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in LLY. Lantz Financial LLC grew its stake in shares of Eli Lilly and Company by 1.3% in the 2nd quarter. Lantz Financial LLC now owns 1,236 shares of the company’s stock worth $1,119,000 after acquiring an additional 16 shares in the last quarter. Private Management Group Inc. increased its stake in shares of Eli Lilly and Company by 11.5% in the second quarter. Private Management Group Inc. now owns 649 shares of the company’s stock worth $588,000 after purchasing an additional 67 shares in the last quarter. Cahill Financial Advisors Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth approximately $200,000. Liberty Wealth Management LLC grew its stake in Eli Lilly and Company by 20.9% in the 2nd quarter. Liberty Wealth Management LLC now owns 1,063 shares of the company’s stock valued at $963,000 after buying an additional 184 shares in the last quarter. Finally, LGT Fund Management Co Ltd. raised its holdings in Eli Lilly and Company by 89.4% during the 2nd quarter. LGT Fund Management Co Ltd. now owns 17,724 shares of the company’s stock valued at $16,047,000 after acquiring an additional 8,367 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now directly owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 target price on shares of Eli Lilly and Company in a report on Monday, September 16th. Redburn Atlantic raised shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Citigroup lifted their price objective on Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research note on Friday, October 25th. Finally, Barclays lowered their price target on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,002.22.

Eli Lilly and Company Trading Up 1.7 %

LLY traded up $12.86 during trading on Wednesday, hitting $786.15. 3,405,092 shares of the stock traded hands, compared to its average volume of 2,942,447. The firm has a 50-day moving average of $788.56 and a 200 day moving average of $861.70. Eli Lilly and Company has a 12-month low of $612.70 and a 12-month high of $972.53. The firm has a market capitalization of $746.30 billion, a P/E ratio of 84.99, a price-to-earnings-growth ratio of 2.99 and a beta of 0.41. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. During the same period in the previous year, the business earned $0.10 earnings per share. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 13.18 EPS for the current year.

Eli Lilly and Company declared that its Board of Directors has initiated a stock buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board of directors believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be paid a $1.50 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a yield of 0.76%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 64.86%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.